Skip to main content

Table 1 Treatment relevant outcomes

From: Treating anxiety after stroke (TASK): the feasibility phase of a novel web-enabled randomised controlled trial

  T0 Baseline (pre-randomisation) T1 follow-up (~ week 6) T2 follow-up primary endpoint (~ week 20)
Demographics *   
Diagnosis (stroke or TIA) *   
Past history of anxiety or depression *   
Medications for anxiety or mood *   
mRS * * *
EQ5D5L-VAS * * *
GAD-7 * * *
PHQ-2 * * *
Modified FQ * * *
Single question on concurrent treatment for mood or anxiety (drug or non-drug) * * *
User feedback survey    *
Sub study of wearing a smartwatch
 Smartwatch for measuring rest/activity Continuous monitoring throughout the trial from T0 to T2
  1. mRS modified Rankin Scale, EQ5D5L-VAS EuroQol-5D5L-Visual analogue score, GAD-7 7-item generalised anxiety disorder questionnaire, PHQ-2 2-item Patient Health Questionnaire, FQ fear questionnaire